GAITHERSBURG, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2014 financial and operating results after the close of U.S. financial markets on Thursday, February 26, 2015.
In addition, management will host a conference call to discuss the quarterly and year-end financial results and provide an update on corporate activities.
| Conference call details are as follows: | |
| Date: | February 26, 2015 |
| Time: | 4:30 pm US Eastern Time |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287–9331 (International) |
| Via web: | www.novavax.com |
| Conference call replay: | |
| Dates: | Starting at 6:31 pm ET on February 26, 2015 until midnight March 5, 2015 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 89629680 |
| Via web: | www.novavax.com, “Investor Info"/"Events” |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations 240-268-2000 ir@novavax.com Novavax, Inc. David Schull or Todd Davenport, Ph.D. Russo Partners, LLC 212-845-4271 david.schull@russopartnersllc.com todd.davenport@russopartnersllc.com
Help employers find you! Check out all the jobs and post your resume.
